

IPW

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 13, 2006.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT
Examining Group 1646
Patent Application
Docket No. ARS-104
Serial No. 10/510,658

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Applicants : Amanda Proudfoot, Marie Kosco-Vilbois, Tracy Handel
Serial No. : 10/510,658
Filed : October 7, 2004
Conf. No. : 9141
For : Novel Antagonists of MCP Proteins

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 U.S.C. § 371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 U.S.C. § 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. In accordance with 37 C.F.R. § 1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/gyl

Attachment: Form PTO/SB/08; copies of cited references.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/510,658
				Filing Date	October 7, 2004
				First Named Inventor	Amanda Proudfoot
				Group Art Unit	1646
				Examiner Name	
				Attorney Docket Number	ARS-104

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R1	HEMMERICH, S. et al. "Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2", <i>Biochemistry</i> , October 5, 1999, pp. 13013-13025, Vol. 38, No. 40.
	R2	STEITZ, S. A. et al. "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis", <i>FEBS Letters</i> , July 3, 1998, pp. 158-164, Vol. 430, No. 3.
	R3	SEET, B. T. et al. "Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor", <i>Proceedings of the National Academy of Sciences of the United States</i> , July 31, 2001, pp. 9008-9013, Vol. 98, No. 16.
	R4	MAYER, M. R. et al. "Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin", <i>Journal of Biological Chemistry</i> , April 27, 2001, pp. 13911-13916, Vol. 276, No. 17.
	R5	CHAKRAVARTY, L. et al. "Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding", <i>Journal of Biological Chemistry</i> , November 6, 1998, pp. 29641-29647, Vol. 273, No. 45.
	R6	DAWSON, J. et al. "Targeting monocyte chemoattractant protein-1 signaling in disease", <i>Expert Opinion on Therapeutic Targets</i> , February 2003, pp. 35-48, Vol. 7, No. 1.
	R7	
	R8	
	R9	
	R10	
	R11	
	R12	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.